Skip to main content
OpenTrials

Clinical trial condition

Primary Myelofibrosis

Explore clinical trials studying Primary Myelofibrosis. Study availability and eligibility vary by location and protocol.

453 public trials 89 recruiting studies
Refine in advanced search Browse all conditions

Primary Myelofibrosis trial results

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Summit Medical Group Oncology Berkeley Heights, New Jersey, United States
  • The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Novartis Investigative Site Buenos Aires, Buenos Aires F.D., Argentina
  • Novartis Investigative Site Capital Federal, Argentina
View all 30 locations
View Trial Details
Recruiting

A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis

NCT07551427

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • The First Affiliated Hospital of University of Science and Technology of China Hefei, Anhui, China
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangzhou First Municipal People's Hospital Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China
View all 24 locations
View Trial Details
Recruiting

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • Hematology Center after Prof.R.H. Yeolyan Yerevan, Armenia
  • University Hospital Halle Department of Hematology/Oncology Halle, Germany
  • University Medicine Hannover Hanover, Germany
  • University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum Minden, Germany
View all 27 locations
View Trial Details
Recruiting

Registry of Older Patients With Cancer

NCT01137825

Conditions
Amyloidosis, Blast Crisis, Blood Coagulation Disorders, +98 more
Locations
  • Seby B. Jones Cancer Center Boone, North Carolina, United States
  • Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States
  • East Carolina University Greenville, North Carolina, United States
  • Pardee Cancer Center Hendersonville, North Carolina, United States
View Trial Details
Recruiting

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

NCT06887803

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +3 more
Locations
  • Azienda Ospedaliero Universitaria Careggi Firenze, Struttura Complessa di Ematologia Florence, Italy
  • IRCCS Clinical Institute Humanitas Rozzano, Milan, Italy
  • Istituto di Ematolgia e Oncologia Medica Bologna, Italy
  • Istituto Romagnolo per lo Studio dei Tumori Meldola, Italy
View Trial Details
Recruiting

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

NCT07340138

Conditions
Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Novartis Investigative Site Kamogawa, Chiba, Japan
  • Novartis Investigative Site Sapporo, Hokkaido, Japan
  • Novartis Investigative Site Kamakura, Kanagawa, Japan
  • Novartis Investigative Site Kurashiki, Okayama-ken, Japan
View Trial Details
Recruiting

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

NCT07469891

Conditions
Bone Marrow Diseases, Bone Marrow Neoplasms, Hematologic Diseases, +13 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • BRCR Global - Coral Springs Coral Springs, Florida, United States
  • START Midwest, LLC Grand Rapids, Michigan, United States
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions